Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2013
15th World Conference on Lung Cancer
Access to all presentations that occurred during the 15th World Conference on Lung Cancer in Sydney, Australia.
Presentation Date(s):- October 27 - 30, 2013
- Total Presentations: 2517
-
+
P1.11 - Poster Session 1 - NSCLC Novel Therapies
- Type: Poster Session
- Track: Medical Oncology
- Presentations: 45
- Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P1.11-037 - Phase II activity of the HSP90 inhibitor AUY922 in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC)
09:30 - 09:30 | Author(s): F. Barlesi
- Abstract
Loading...
-
+
MO08 - NSCLC - Early Stage
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 12
- Moderators:K. Nakagawa
- Coordinates: 10/28/2013, 16:15 - 17:45, Bayside Gallery B, Level 1
-
+
MO08.02 - Adjuvant pazopanib or placebo in resected stage I NSCLC patients: results of the NSCLC adjuvant randomized phase II trial (IFCT-0703) from the French collaborative Intergroup
16:20 - 16:25 | Author(s): B. Besse
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
MO18 - NSCLC - Targeted Therapies IV
- Type: Mini Oral Abstract Session
- Track: Medical Oncology
- Presentations: 13
- Moderators:L. Horn
- Coordinates: 10/29/2013, 16:15 - 17:45, Bayside Auditorium B, Level 1
-
+
MO18.10 - Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with pemetrexed in a phase 1/1B trial involving KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): efficacy and biomarker results
17:10 - 17:15 | Author(s): J. Mazieres
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
P3.09 - Poster Session 3 - Combined Modality
- Type: Poster Session
- Track: Combined Modality
- Presentations: 18
- Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level
-
+
P3.09-018 - IFCT-0803 Trial: a phase II study of cetuximab, pemetrexed, cisplatin and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC): preliminary safety analysis
09:30 - 09:30 | Author(s): J. Tredaniel
- Abstract
Loading...
-
+
Best of Posters - IASLC Selection - Part 2
- Type: Exhibit Showcase Session
- Track:
- Presentations: 4
- Coordinates: 10/30/2013, 09:55 - 10:25, Exhibit Hall, Ground Level
-
+
P2.11-024 - Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non- small Cell Lung Cancer (NSCLC)
10:00 - 10:05 | Author(s): S. Novello
- Abstract
Loading...
